ACICLOVIR AGILA aciclovir (as sodium) 250 mg powder for injection vial

Country: Australia

Language: English

Source: Department of Health (Therapeutic Goods Administration)

Active ingredient:

aciclovir sodium dihydrate, Quantity: 314.4 mg (Equivalent: aciclovir, Qty 250 mg)

Available from:

Alphapharm Pty Ltd

Pharmaceutical form:

Injection, powder for

Composition:

Excipient Ingredients:

Administration route:

Intravenous

Units in package:

5 vials

Prescription type:

(S4) Prescription Only Medicine

Therapeutic indications:

Aciclovir Agila (aciclovir sodium) is indicated for:,- Promoting resolution of acute clinical manifestations of mucocutaneous Herpes simplex virus infections in immunocompromised patients,- Treatment of severe first episode primary or non-primary genital herpes in immune competent patients,- Treatment of acute manifestations of Varicella zoster virus infection in immunocompromised patients,- Treatment of Herpes zoster (shingles) in immune competent patients who show very severe acute local or systemic manifestations of the disease. (Benefits can be expected in patients with rash duration shorter than 72 hours. The use of the intravenous infusion may be warranted in only a small subgroup of immune competent patients with shingles).,- Treatment of Herpes simplex encephalitis.

Product summary:

Visual Identification: White to off-white lyophilized powder or cake; Container Type: Vial; Container Material: Glass Type I Clear; Container Life Time: 24 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert

Authorization status:

Registered

Authorization date:

2021-05-28